ArticleCancer biomarkers : section A of Disease markers2021
DEPDC1 upregulation promotes cell proliferation and predicts poor prognosis in patients with gastric cancer.
Article in Cancer biomarkers : section A of Disease markers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 22 citations in OpenAlex.
- Methylation-regulated miR-374a-5p and miR-374b-5p suppress glycolysis and malignant progression of head and neck squamous cell carcinoma by targeting DEPDC1.Frontiers in oncology · 2026Article
- DEP domain containing 1: a potential oncogenic driver.Biological research · 2025Article
- YY1-mediated DUXAP8 facilitates HCC progression via modulating DEPDC1 expression.Clinical and experimental medicine · 2025Article
- Roles of DEPDC1 in various types of cancer (Review).Oncology letters · 2024Review
- Wnt/β-Catenin Signaling Pathway in Pediatric Tumors: Implications for Diagnosis and Treatment.Children (Basel, Switzerland) · 2024Review
- Article
- Pan-cancer prognostic model and immune microenvironment analysis of natural killer cell-related genes.Translational cancer research · 2024Article
- Article
- Article
- Article
- DEPDC1 and KIF4A synergistically inhibit the malignant biological behavior of osteosarcoma cells through Hippo signaling pathway.Journal of orthopaedic surgery and research · 2023Article
- Glycolysis-Related Gene Analyses Indicate That DEPDC1 Promotes the Malignant Progression of Oral Squamous Cell Carcinoma via the WNT/β-Catenin Signaling Pathway.International journal of molecular sciences · 2023Article
- Pan-cancer analysis ofAnnals of translational medicine · 2022Article
- FOXO3a‑modulated DEPDC1 promotes malignant progression of nephroblastoma via the Wnt/β‑catenin signaling pathway.Molecular medicine reports · 2022Article
- The Pan-Cancer Crosstalk Between theFrontiers in cell and developmental biology · 2022Article
- FOXM1 is regulated by DEPDC1 to facilitate development and metastasis of oral squamous cell carcinoma.Frontiers in oncology · 2022Article
- miR-455-5p enhances 5-fluorouracil sensitivity in colorectal cancer cells by targeting PIK3R1 and DEPDC1.Open medicine (Warsaw, Poland) · 2022Article
- [DEPDC1 is Highly Expressed in Lung Adenocarcinoma and Promotes Tumor Cell Proliferation].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrevious studies revealed that DEP domain containing 1 (DEPDC1) is involved in the carcinogenesis and progression of several types of human cancer. However the role of DEPDC1 in gastric cancer has not been studied.
objectiveThe objective of this study was to study the expression and pathophysiological function of DEPDC1 in gastric cancer.
methodsDEPDC1 expression in gastric adenocarcinoma cells was examined with Western blot and qRT-PCR. Clinical pathological features of patients were determined by immunohistochemistry. The effect of DEPDC1 expression on cell proliferation was studied by in vitro cell proliferation assay; and cell cycle influence was assessed by flow cytometry. Survival curves were plotted using Kaplan-Meier.
resultsDEPDC1 was overexpressed in gastric adenocarcinoma tissues compared with the paired adjacent normal gastric tissues, in accordance with mRNA level downloaded from GEPIA database. DEPDC1 expression level was significantly associated with cancer metastasis and differentiation. DEPDC1 upregulation caused cell cycle accelerating from G1 to S phase, and it was correlated with poorer overall survival.
conclusionTherefore, DEPDC1 upregulation in gastric adenocarcinoma is associated with tumor development and poor clinical outcomes of the patients, implying DEPDC1 might be a potential therapeutic target against gastric cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.